T. Rowe Price Associates
CAPR icon

T. Rowe Price Associates’s Capricor Therapeutics CAPR Stock Holding History

T. Rowe Price Associates’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$943K Buy
30,995
+7,843
+34% +$209K ﹤0.01% 2190
2025
Q4 		$669K Buy
23,152
+2,578
+13% +$33.7K ﹤0.01% 2268
2025
Q3 		$149K Buy
20,574
+1,556
+8% +$11.5K ﹤0.01% 2851
2025
Q2 		$189K Buy
19,018
+3,490
+22% +$36.9K ﹤0.01% 2733
2025
Q1 		$148K Buy
15,528
+1,286
+9% +$17.9K ﹤0.01% 2733
2024
Q4 		$197K Buy
+14,242
New +$250K ﹤0.01% 2688

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

T. Rowe Price Associates's CAPR Position: Q1 2026 in Review

T. Rowe Price Associates increased its Capricor Therapeutics (CAPR) stake by 34% in Q1 2026, buying an estimated $209K and bringing the position to 30,995 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

T. Rowe Price Associates first reported a position in CAPR in Q4 2024 and has held it in 6 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • T. Rowe Price Associates held 30,995 shares of Capricor Therapeutics worth $943K as of Q1 2026.
  • T. Rowe Price Associates bought 7,843 Capricor Therapeutics shares in Q1 2026, an estimated $209K.
  • Capricor Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2190 holding.
  • T. Rowe Price Associates first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.